Qingquan Chen

Long non-coding RNA LINC00858 aggravates the oncogenic phenotypes of ovarian cancer cells through miR-134-5p/RAD18 signaling

Ovarian cancer is a common gynecological cancer. Herein, we focused on the function and probable mechanisms of LINC00858 in ovarian cancer. Real-time quantitative polymerase chain reaction (RT-qPCR) was employed for detecting the expression of LINC00858, miR-134-5p and RAD18 E3 ubiquitin protein ligase (RAD18). Cell proliferation, migration, invasion, epithelial-mesenchymal transition (EMT) and apoptosis were detected by cell counting kit-8 (CCK-8), 5-ethynyl-2'-deoxyuridine (EdU), transwell, terminal deoxynucleotidyl transferase (TdT) dUTP Nick-End Labeling (TUNEL) and western bolt experiments, as appropriate. Interplays between LINC00858, miR-134-5p and RAD18 were detected by RNA immunoprecipitation (RIP), RNA pull down and luciferase reporter assays. LINC00858 were up-regulated in ovarian cancer tissues and cells, and its expression was elevated in advanced samples compared to early ones. Knocking down LINC00858 inhibited cell proliferation, motility and EMT, but accelerated cell apoptosis in ovarian cancer. Moreover, could be sponged by LINC00858 sponged miR-134-5p to enhance RAD18 expression in ovarian cancer. Also, silenced RAD18 could also restrain oncogenic behaviors of ovarian cancer cells. Rescue experiments showed that overexpressing RAD18 reversed the effects caused by knocking down LINC00858 on cellular processes. LINC00858 sequestered miR-134-5p to elevate RAD18 expression, resulting in aggravated development of ovarian cancer. This might provide promising targets for treating patients with ovarian cancer.

Temporal Trends in Cervical Human Papillomavirus Prevalence Among Females in Xiamen, China (2016-2023): Cross-Sectional Study

Abstract Background Human papillomavirus (HPV) is a primary causative agent of cervical cancer, accounting for more than 90% of cases worldwide. Epidemiological data on regional HPV prevalence and genotype distribution are critical for tailoring targeted cervical cancer prevention strategies, particularly in regions with limited population-based studies. Objective This study aimed to investigate temporal trends in the prevalence of overall HPV infection and vaccine-targeted HPV genotypes among females in Xiamen between 2016 and 2023 using annual cross-sectional analyses. Methods We analyzed retrospective deidentified data from 63,553 females who underwent HPV genotyping of cervical exfoliated cells at Zhongshan Hospital affiliated with Xiamen University from 2016 to 2023. Data on HPV genotyping, age, and detection time were collected from the hospital’s electronic information system. For each year, we conducted a cross-sectional assessment of HPV infection status to calculate annual HPV prevalence. Temporal trends of HPV prevalence were analyzed across 3 pandemic periods (prepandemic: 2016‐2019, pandemic: 2020‐2022, and postpandemic: 2023) and by age groups. Results The overall HPV prevalence was 25.24% (16,039/63,553), comprising high-risk human papillomavirus (HR-HPV) at 19.26% (12,242/63,553) and low-risk human papillomavirus (LR-HPV) at 10.08% (6409/63,553). Vaccine-targeted HPV prevalence rates were bivalent human papillomavirus at 3.56% (2264/63,553), quadrivalent human papillomavirus at 5.89% (3746/63,553), and nine-valent human papillomavirus at 13.64% (8666/63,553), respectively. Notably, the number of non–vaccine-targeted HPV genotypes accounted for 16.01% (10,177/63,553) of all tested females and 63.45% (10,177/16,039) of HPV-positive cases. The top 5 HR-HPV genotypes were HPV52 (3000/63,553, 4.72%), HPV58 (1895/63,553, 2.98%), HPV53 (1582/63,553, 2.49%), HPV16 (1461/63,553, 2.30%), and HPV39 (1116/63,553, 1.76%), while HPV81 (1407/63,553, 2.21%), HPV61 (1268/63,553, 2%), and HPV6 (1101/63,553, 1.73%) were the most prevalent LR-HPV genotypes. Temporal analysis revealed significant declines in the prevalence of overall HPV, HR-HPV, LR-HPV, bivalent human papillomavirus, quadrivalent human papillomavirus, nine-valent human papillomavirus, and specific genotypes (HPV52, HPV58, HPV16, HPV39, and HPV6) from 2016 to 2019 to 2023 (all P<.001). Conversely, HPV81 prevalence increased significantly in 2023 compared to 2020‐2022 (2.44% vs 1.96%; P<.001). Age-stratified analysis of HPV prevalence showed a significant declining trend with increasing age (P<.001), with peak prevalence observed in the ≤20-year age group. Conclusions Cervical HPV infection, particularly non–vaccine-targeted genotypes, remains a substantial public health burden in Xiamen, highlighting the urgency to develop broader spectrum vaccines, to enhance cervical cancer screening programs, and to implement age-specific interventions, specifically for females aged ≤20 years. Long-term surveillance of emerging HPV genotypes and vaccination coverage is recommended.